# OnCo record geicam-ciboma (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/geicam-ciboma/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "geicam-ciboma", "NCT00130533" ;
  schema:name "GEICAM/2003-11_CIBOMA/2004-01"@en ;
  schema:alternateName "CIBOMA"@en, "GEICAM/CIBOMA"@en, "GEICAM 2003-11"@en ;
  schema:description "This Spanish and Latin American trial gave eight extra cycles of capecitabine after standard chemotherapy for early triple-negative breast cancer and did not significantly reduce relapses. Only tumours without the basal-like pattern seemed to benefit, a finding that still needs confirmation."@en ;
  schema:url <https://onco.cc/trials/geicam-ciboma/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00130533>, <https://doi.org/10.1200/JCO.19.00904> ;
  onco:status "negative" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-early/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/capecitabine/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/geicam/> ;
  onco:terms <https://onco.cc/terms/efs/> ;
  onco:trials <https://onco.cc/trials/create-x/>, <https://onco.cc/trials/sysucc-001/> .